MHRA Medicines and Healthcare products Regulatory Agency _Paxlovid: be alert to the risk of drug interactions with ritonavir

Nirmatrelvir, ritonavir (Paxlovid) : be alert to the risk of drug interactions with ritonavir
There is a risk of harmful drug interactions with the ritonavir component of the Covid-19 treatment Paxlovid due to its inhibition of the enzyme CYP3A, which metabolises many commonly used drugs. Prescribers should obtain a detailed patient history of current medications before prescribing Paxlovid, checking the Paxlovid product information for known and potential drug interactions.

For further information please visit https://www.gov.uk/drug-safety-update/nirmatrelvir-ritonavir-paxlovidv-be-alert-to-the-risk-of-drug-interactions-with-ritonavir